(2R,3R,4S)-3-[(tert-Butoxycarbonyl)amino]-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid | 464179-59-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,3R,4S)-3-[(tert-Butoxycarbonyl)amino]-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
• 英文别名: (2R,3R,4S)-4-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
• CAS: 464179-59-7
• 化学式: C₁₄H₂₃NO₉
• 分子量: 349.338
• InChiKey: NDKWDQBAXLRRRC-CNYIRLTGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  166
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (2R,3R,4S)-3-[(tert-Butoxycarbonyl)amino]-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid 在 吡啶 、 sodium methylate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.5h， 生成 (1S,2R)-1-((2R,3R,4S)-4-acetoxy-3-(2-azidoacetamido)-6-(methoxycarbonyl)-3,4-dihydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate
  参考文献：
  名称：

  Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid

  摘要：

  We report the synthesis of a series of C9 and N5Ac modified analogs of 2,3-didehydro-N-acetyl-neuraminic acid (DANA) and their inhibitory potency for the human neuraminidase 3 (NEU3) enzyme. We were able to generate a small library of compounds through the synthesis of azide derivatives of DANA, followed by Cu-catalyzed azide-alkyne cycloaddition (CuAAC) to generate triazole-containing inhibitors. Our results suggest that NEU3 can tolerate large hydrophobic groups at the C9 position; however, none of the derivatives made at the N5Ac side-chain were active. We identify three new inhibitors that have comparable potency to the best reported inhibitors of the enzyme. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.111
• 作为产物：
  描述：

  (1S,2R)-1-((2R,3R,4S,6R)-3-acetamido-4,6-diacetoxy-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate 在 盐酸 、 4-二甲氨基吡啶 、 sodium hydroxide 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 苯 为溶剂， 反应 56.0h， 生成 (2R,3R,4S)-3-[(tert-Butoxycarbonyl)amino]-4-hydroxy-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
  参考文献：
  名称：

  低聚物从酰胺连接的神经氨酸衍生类似物的合成＃

  摘要：

  已经制备了由α - O-甲氧基-和2，3-脱氢尿嘧啶酸衍生的N-氟人-9-基甲氧基羰基保护的糖氨基酸。将这些单体单元结合到固相合成中导致有效合成长度从一到八个单元的两个系列的低聚物。将2，3-脱氢尿嘧啶酸的（1→5）-连接的酰胺进一步进行氢化，得到在异头碳处具有β-氢取代基的第三系列低聚物。

  DOI：

  10.1021/jo035312+

文献信息

• Compounds useful for inhibiting paramyxovirus neuraminidase
  申请人：——

  公开号：US20030187063A1

  公开（公告）日：2003-10-02

  Compounds represented by the formula: 1 wherein X is selected from the group consisting of: CHR, O, NR, N—OR, NR(O), S, S(O) and S(O)O X 1 is selected from the group consisting of CR, N, and N(O); R is selected from the group consisting of: H, alkyl, alkene, alkyne, CN, NO 2 , N 3 , halo and NHR 10 ; R 1 is selected from the group consisting of: H, (CH 2 )nCO 2 R 10 , (CH 2 )n-tetrazol, (CH 2 )nSO 3 H, (CH 2 )nSO 2 H, (CH 2 )nPO 3 H 2 , (CH 2 )nCONR 10 , (CH 2 )nNO 2 , and (CH 2 )nCHO; R 1a is selected from the group consisting of: H, (CH 2 )nOR 10 , (CH 2 )nCN, (CH 2 )nNR 10 R 10a , (CH 2 )nNHC(O)R 10 , (CH 2 )nC(O)NR 10 R 10a , and (CH 2 )nOC(O)R 10 ; R 1 and R 1a both cannot be H each of R 2 and R 2a is independently selected from the group consisting of H, halo, CN, (CH 2 )nCO 2 R 10 , (CH 2 )nNR 10 R 10a and (CH 2 ) n —OR 10 ; each of R 3 and R 3a is independently selected from the group consisting of: H, NHSO 2 R 10 , N(O)—SO 2 R 10 , NR 10 SO 2 R 10a , (CH 2 )mYR 10 , and (CH 2 )mR 6 ; at least one of R 3 and R 3a should be other than H Y is selected from the group consisting of: O, NH, NHC(O), C(O)NH, S, S(O), S(O)O, NHS(O)O, S(O)ONH, NHC(O)NH and heterocycle; R 3 and R 3a together may be ═O, ═CHR 6 , ═CHR 10 , ═NR 10 , NR 10 and ═N—OR 10 R 4 and R 4a is independently selected from the group consisting of: H, (CH 2 )mYR 10 and (CH 2 )mR 6 R 4 and R 4a together may be: ═O, ═CHR 6 , ═CHR 10 , ═NR 10 and ═N—OR 10 each of R 5 and R 5a is independently selected from the group consisting of C(R 7 )(R 7a ), C(R 7 )(R 7a )C(R 8 )(R 8a ), C(R 7 )(R 7a )C(R 8 )(R 8a )C(R 9 )(R 9a ), OC(R 7 )(R 7a ), OC(R 7 )(R 7a )C(R 8 )(R 8a ), C(R 7 )(R 7a )OC(R 8 )(R 8a ), N(R 10 )C(R 7 )(R 7a ), N(R 10 ) C(R 7 )(R 7a )C(R 8 )(R 8a ), C(R 7 )(R 7a )N(R 10 )C(R 8 )(R 8a ), and C(O)NR 10 R 10a ; R 6 is selected from the group consisting of H, halo, CN, NO 2 , N 3 , CO 2 R 10 , R 10 and NR 10 R 10a ; R 7 , R 7a , R 8 , R 8a , R 9 and R 9a is selected from the group from the group consisting of: H, (CH 2 )mYR 10 and (CH 2 )mR 6 each of the R 10 and R 10a is individually selected from the groups consisting of: H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, alkenyl, substituted alkenyl, alkynyl, and substituted alkynyl; Each of m and n is individually 0, 1, 2, 3, or 4; and pharmaceutically acceptable salt thereof; and prodrugs thereof, and uses thereof.

  该化合物的结构式为：1，其中X从以下组中选择：CHR，O，NR，N—OR，NR（O），S，S（O）和S（O）OX1从以下组中选择：CR，N和N（O）；R从以下组中选择：H，烷基，烯烃，炔烃，CN，NO2，N3，卤素和NHR10；R1从以下组中选择：H，（CH2）nCO2R10，（CH2）n-四唑，（CH2）nSO3H，（CH2）nSO2H，（CH2）nPO3H2，（CH2）nCONR10，（CH2）nNO2和（CH2）nCHO；R1a从以下组中选择：H，（CH2）nOR10，（CH2）nCN，（CH2）nNR10R10a，（CH2）nNHC（O）R10，（CH2）nC（O）NR10R10a和（CH2）nOC（O）R10；R1和R1a都不能是H；R2和R2a各自从H，卤素，CN，（CH2）nCO2R10，（CH2）nNR10R10a和（CH2）n—OR10中选择；R3和R3a各自从H，NHSO2R10，N（O）—SO2R10，NR10SO2R10a，（CH2）mYR10和（CH2）mR6中选择；其中至少有一个R3和R3a不是H，Y从以下组中选择：O，NH，NHC（O），C（O）NH，S，S（O），S（O）O，NHS（O）O，S（O）ONH，NHC（O）NH和杂环；R3和R3a可以组成&boxH；O，&boxH；CHR6，&boxH；CHR10，&boxH；NR10，NR10和&boxH；N—OR10；R4和R4a各自从H，（CH2）mYR10和（CH2）mR6中选择；其中R5和R5a各自从C（R7）（R7a），C（R7）（R7a）C（R8）（R8a），C（R7）（R7a）C（R8）（R8a）C（R9）（R9a），OC（R7）（R7a），OC（R7）（R7a）C（R8）（R8a），C（R7）（R7a）OC（R8）（R8a），N（R10）C（R7）（R7a），N（R10）C（R7）（R7a）C（R8）（R8a），C（R7）（R7a）N（R10）C（R8）（R8a）和C（O）NR10R10a中选择；R6从以下组中选择：H，卤素，CN，NO2，N3，CO2R10，R10和NR10R10a；R7、R7a、R8、R8a、R9和R9a从以下组中选择：H，（CH2）mYR10和（CH2）mR6；R10和R10a各自从以下组中选择：H，烷基，取代烷基，芳基，取代芳基，芳基烷基，取代芳基烷基，杂环，取代杂环，烯基，取代烯基，炔基和取代炔基；m和n各自为0、1、2、3或4；以及其药学上可接受的盐和前药，以及其用途。
• Saludes, Jonel P.; Ames, James B.; Gervay-Hague, Jacquelyn, Journal of the American Chemical Society, 2009, vol. 131, p. 5495 - 5505
  作者：Saludes, Jonel P.、Ames, James B.、Gervay-Hague, Jacquelyn

  DOI：——

  日期：——
• US7045535B2
  申请人：——

  公开号：US7045535B2

  公开（公告）日：2006-05-16
• Synthesis of Oligomers Derived from Amide-Linked Neuraminic Acid Analogues
  作者：Travis Q. Gregar、Jacquelyn Gervay-Hague

  DOI：10.1021/jo035312+

  日期：2004.2.1

  N-Fluoren-9-ylmethoxycarbonyl-protected sugar amino acids derived from α-O-methoxy- and 2,3-dehydroneuraminic acids have been prepared. Incorporation of these monomer units into solid-phase synthesis led to the efficient synthesis of two series of oligomers varying from one to eight units in length. The (1→5)-linked amides of 2,3-dehydroneuraminic acid were further subjected to hydrogenation giving a

  已经制备了由α - O-甲氧基-和2，3-脱氢尿嘧啶酸衍生的N-氟人-9-基甲氧基羰基保护的糖氨基酸。将这些单体单元结合到固相合成中导致有效合成长度从一到八个单元的两个系列的低聚物。将2，3-脱氢尿嘧啶酸的（1→5）-连接的酰胺进一步进行氢化，得到在异头碳处具有β-氢取代基的第三系列低聚物。
• Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid
  作者：Yao Zou、Amgad Albohy、Mahendra Sandbhor、Christopher W. Cairo

  DOI：10.1016/j.bmcl.2010.09.111

  日期：2010.12

  We report the synthesis of a series of C9 and N5Ac modified analogs of 2,3-didehydro-N-acetyl-neuraminic acid (DANA) and their inhibitory potency for the human neuraminidase 3 (NEU3) enzyme. We were able to generate a small library of compounds through the synthesis of azide derivatives of DANA, followed by Cu-catalyzed azide-alkyne cycloaddition (CuAAC) to generate triazole-containing inhibitors. Our results suggest that NEU3 can tolerate large hydrophobic groups at the C9 position; however, none of the derivatives made at the N5Ac side-chain were active. We identify three new inhibitors that have comparable potency to the best reported inhibitors of the enzyme. (C) 2010 Elsevier Ltd. All rights reserved.